{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:56:43Z","timestamp":1790629003850,"version":"4.1.0"},"reference-count":64,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1001\/jamainternmed.2020.0555","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T15:31:07Z","timestamp":1585582267000},"page":"769","source":"Crossref","is-referenced-by-count":83,"title":["Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis"],"prefix":"10.1001","volume":"180","author":[{"given":"Brad","family":"Spellberg","sequence":"first","affiliation":[{"name":"Los Angeles County + University of Southern California Medical Center, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Musher","sequence":"additional","affiliation":[{"name":"Infectious Disease Section, Department of Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Allegheny General Hospital, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S.","family":"Bayer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Torrance, California"},{"name":"The Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"irv200001r2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.7326\/0003-4819-19-5-787","article-title":"Treatment of subacute bacterial endocarditis: current results.","volume":"19","author":"Lichtman","year":"1943","journal-title":"Ann Intern Med"},{"issue":"10","key":"irv200001r3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJM195403112501005","article-title":"Treatment of bacterial endocarditis.","volume":"250","author":"Finland","year":"1954","journal-title":"N Engl J Med"},{"issue":"9","key":"irv200001r4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1056\/NEJM195403042500906","article-title":"Treatment of bacterial endocarditis.","volume":"250","author":"Finland","year":"1954","journal-title":"N Engl J Med"},{"key":"irv200001r5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jama.1937.02780120023005","article-title":"Para-aminobenzenesulfonamide: absorption and excretion: method of determination in urine and blood.","volume":"108","author":"Marshall","year":"1937","journal-title":"JAMA"},{"issue":"12","key":"irv200001r6","first-page":"732","article-title":"The clinical use of sulfanilamide and its derivatives in the treatment and prophylaxis of certain infections: the Wesley M. Carpenter Lecture.","volume":"16","author":"Long","year":"1940","journal-title":"Bull N Y Acad Med"},{"issue":"2","key":"irv200001r7","first-page":"81","article-title":"Sulfanilamide and sulfapyridin in the treatment of various infections: part I.","volume":"51","author":"Keefer","year":"1939","journal-title":"Cal West Med"},{"issue":"4","key":"irv200001r8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.7326\/0003-4819-11-4-575","article-title":"The clinical use of sulphanilamide and its derivatives in the treatment of infectious diseases.","volume":"11","author":"Long","year":"1937","journal-title":"Ann Intern Med"},{"issue":"5","key":"irv200001r9","first-page":"457","article-title":"Observations upon the experimental and clinical use of sulphanilamide in the treatment of certain infections.","volume":"37","author":"Long","year":"1937","journal-title":"CMAJ"},{"key":"irv200001r11","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"irv200001r12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02411-16","article-title":"Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe.","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"irv200001r13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1128\/AAC.40.4.891","article-title":"Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.","volume":"40","author":"Doern","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"irv200001r14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1046\/j.1198-743x.2001.00230.x","article-title":"Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.","volume":"7","author":"Diekema","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"irv200001r15","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1128\/AAC.00294-08","article-title":"Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.","volume":"52","author":"Jones","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"irv200001r16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1086\/424506","article-title":"A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection.","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"10","key":"irv200001r17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/0036554021000026933","article-title":"Linezolid versus ceftriaxone\/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia.","volume":"34","author":"San Pedro","year":"2002","journal-title":"Scand J Infect Dis"},{"issue":"8","key":"irv200001r18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid versus vancomycin for treatment of resistant gram-positive infections in children.","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"irv200001r19","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1097\/01.inf.0000086956.45566.55","article-title":"Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.","volume":"22","author":"Jantausch","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"irv200001r20","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1097\/01.inf.0000086955.93702.c7","article-title":"Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.","volume":"22","author":"Deville","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"irv200001r21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/597199","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"irv200001r22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections.","volume":"53","author":"Wilcox","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"irv200001r23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.ajkd.2012.07.003","article-title":"Peripherally inserted central catheters and other intravascular devices: how safe are they for hemodialysis patients?","volume":"60","author":"Shingarev","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"irv200001r24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/bmjqs-2018-008726","article-title":"Patient-reported complications related to peripherally inserted central catheters: a multicentre prospective cohort study.","volume":"28","author":"Krein","year":"2019","journal-title":"BMJ Qual Saf"},{"key":"irv200001r25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13756-016-0161-0","article-title":"Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study.","volume":"6","author":"Grau","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"irv200001r26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00592-016-0953-y","article-title":"Association between microfibrillar-associated protein 4 (MFAP4) and micro- and macrovascular complications in long-term type 1 diabetes mellitus.","volume":"54","author":"Blindb\u00e6k","year":"2017","journal-title":"Acta Diabetol"},{"issue":"3","key":"irv200001r27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults.","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"irv200001r28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40119-019-00148-4","article-title":"Current evidence on oral antibiotics for infective endocarditis: a narrative review.","volume":"8","author":"Kobayashi","year":"2019","journal-title":"Cardiol Ther"},{"issue":"5","key":"irv200001r29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.12788\/jhm.2949","article-title":"When are oral antibiotics a safe and effective choice for bacterial bloodstream infections? an evidence-based narrative review.","volume":"13","author":"Hale","year":"2018","journal-title":"J Hosp Med"},{"key":"irv200001r30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2334-14-140","article-title":"Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review.","volume":"14","author":"Al-Omari","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"10","key":"irv200001r31","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1007\/s10096-012-1597-7","article-title":"Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study.","volume":"31","author":"Lauridsen","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"irv200001r32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1179\/joc.2009.21.3.311","article-title":"Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin.","volume":"21","author":"Tascini","year":"2009","journal-title":"J Chemother"},{"key":"irv200001r33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJM196104272641701","article-title":"Subacute bacterial endocarditis: clinical and laboratory observations in 27 consecutive cases treated with penicillin V by mouth.","volume":"264","author":"Quinn","year":"1961","journal-title":"N Engl J Med"},{"key":"irv200001r34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/pgmj.40.Suppl.105","article-title":"Treatment of bacterial endocarditis with oral penicillins.","volume":"40","author":"Gray","year":"1964","journal-title":"Postgrad Med J"},{"key":"irv200001r35","first-page":"873","article-title":"Oral treatment of malignant streptococcal endocarditis by potassium phenethicillin: 10 cases","volume":"92","author":"Campeau","year":"1963","journal-title":"Union Med Can"},{"issue":"5067","key":"irv200001r36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/bmj.1.5067.377","article-title":"Treatment of subacute bacterial endocarditis with oral phenoxymethylpenicillin.","volume":"1","author":"Sandler","year":"1958","journal-title":"BMJ"},{"issue":"6","key":"irv200001r37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJM195708082570601","article-title":"Oral treatment of subacute bacterial endocarditis with phenoxymethyl penicillin (penicillin V).","volume":"257","author":"Santos-Buch","year":"1957","journal-title":"N Engl J Med"},{"issue":"11","key":"irv200001r38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jama.1956.02960460009003","article-title":"Phenoxymethyl penicillin (penicillin V) therapy of subacute bacterial endocarditis.","volume":"160","author":"Quinn","year":"1956","journal-title":"JAMA"},{"issue":"2","key":"irv200001r39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijantimicag.2019.06.006","article-title":"High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis.","volume":"54","author":"Tissot-Dupont","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"irv200001r40","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cmi.2016.04.003","article-title":"Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients.","volume":"22","author":"Mzabi","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"irv200001r41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/adc.52.3.235","article-title":"Oral treatment of subacute bacterial endocarditis in children.","volume":"52","author":"Phillips","year":"1977","journal-title":"Arch Dis Child"},{"issue":"7","key":"irv200001r42","first-page":"646","article-title":"Oral treatment of bacterial endocarditis.","volume":"19","author":"Pinchas","year":"1983","journal-title":"Isr J Med Sci"},{"issue":"12","key":"irv200001r43","first-page":"709","article-title":"High-dose oral amoxycillin in the treatment of infective endocarditis.","volume":"73","author":"Chetty","year":"1988","journal-title":"S Afr Med J"},{"issue":"8671","key":"irv200001r44","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0140-6736(89)91083-0","article-title":"Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin.","volume":"2","author":"Dworkin","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"irv200001r45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.athoracsur.2007.02.096","article-title":"Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis.","volume":"84","author":"Colli","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"irv200001r46","doi-asserted-by":"publisher","first-page":"832","DOI":"10.7326\/0003-4819-93-6-832","article-title":"Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis.","volume":"93","author":"Parker","year":"1980","journal-title":"Ann Intern Med"},{"issue":"7","key":"irv200001r47","first-page":"374","article-title":"Streptococcal endocarditis treated with two-week antibiotic regimen: preliminary report of a partial oral regimen.","volume":"76","author":"Chayakul","year":"1993","journal-title":"J Med Assoc Thai"},{"issue":"10","key":"irv200001r48","first-page":"559","article-title":"Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis.","volume":"76","author":"Chayakul","year":"1993","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"irv200001r49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/jac\/dkl219","article-title":"Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.","volume":"58","author":"Falagas","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"irv200001r50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/jac\/dkq506","article-title":"Linezolid for endocarditis: a case series of 14 patients.","volume":"66","author":"Tascini","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"irv200001r51","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jinf.2005.05.022","article-title":"Treatment of prosthetic valve infective endocarditis due to multi-resistant gram-positive bacteria with linezolid.","volume":"52","author":"Wareham","year":"2006","journal-title":"J Infect"},{"issue":"2","key":"irv200001r52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1469-0691.2006.01585.x","article-title":"Linezolid therapy for infective endocarditis.","volume":"13","author":"Mu\u00f1oz","year":"2007","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"irv200001r53","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.medmal.2011.08.003","article-title":"Audit of antibiotic therapy used in 66 cases of endocarditis.","volume":"41","author":"Demonchy","year":"2011","journal-title":"Med Mal Infect"},{"key":"irv200001r54","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1093\/clinids\/13.Supplement_2.S160","article-title":"Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci.","volume":"13","author":"Stamboulian","year":"1991","journal-title":"Rev Infect Dis"},{"issue":"1","key":"irv200001r55","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy.","volume":"101","author":"Heldman","year":"1996","journal-title":"Am J Med"},{"key":"irv200001r56","doi-asserted-by":"publisher","first-page":"S428","DOI":"10.1093\/clinids\/5.Supplement_3.S428","article-title":"Pharmacokinetics and metabolism of rifampin in humans.","volume":"5","author":"Acocella","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"5","key":"irv200001r57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis.","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"irv200001r58","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1056\/NEJMc1902096","article-title":"Long-term outcomes of partial oral treatment of endocarditis.","volume":"380","author":"Bundgaard","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"irv200001r59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214037","article-title":"Effects of a rifampicin pre-treatment on linezolid pharmacokinetics.","volume":"14","author":"Okazaki","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"irv200001r60","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0091270010366445","article-title":"Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.","volume":"51","author":"Gandelman","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"irv200001r61","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJMc1904725","article-title":"Partial oral therapy for osteomyelitis and endocarditis.","volume":"381","author":"Musher","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"irv200001r62","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/jama.2016.1346","article-title":"New societal approaches to empowering antibiotic stewardship.","volume":"315","author":"Spellberg","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"irv200001r63","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \u201cstatic vs cidal\u201d: a systemic literature review.","volume":"66","author":"Wald-Dickler","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"9","key":"irv200001r64","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic mantra\u2014\u201cshorter is better\u201d.","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"irv200001r1","volume-title":"The Sulfonamides and Allied Compounds","author":"Northey","year":"1948"},{"key":"irv200001r10","volume-title":"The Sanford Guide to Antimicrobial Therapy","author":"Gilbert","year":"2019"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2763415\/jamainternal_spellberg_2020_rv_200001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T23:56:51Z","timestamp":1666223811000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2763415"}},"subtitle":["A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2020.0555","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}